Synapse Open Synapse
Biology

Windward prices $175M IPO to advance China-licensed lung drugs

BioPharma Dive · · 2 min read

The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.

Latest from BioPharma Dive